AI Article Synopsis

  • A 61-year-old woman was diagnosed with matrix-producing carcinoma (MPC) of the right breast after a 19 mm mass was found; imaging showed characteristic rim enhancement around the tumor.
  • Core needle biopsy confirmed the malignancy, which was classified as triple negative breast cancer (ER-, PgR-, HER2-), and the patient underwent breast-conserving surgery with sentinel lymph node biopsy.
  • Despite a poorer prognosis compared to typical breast cancer, the patient remained recurrence-free for five years post-surgery, receiving only radiation therapy for treatment.

Article Abstract

A 61-year-old woman was referred to our hospital because of a right breast mass. A 19 mm hard mass was palpable in the A area of the right breast. A contrast-enhanced MRI showed rim enhancement at the peripheral region of the tumor, which was thought to represent the carcinoma component mainly at the periphery and the matrix component inside the tumor. A low density mass with rim enhancement at the peripheral region was observed in a contrast-enhanced CT, the same as in the MRI. Neither axillary lymph node metastasis nor distant metastasis was observed. A core needle biopsy of the tumor lead to a diagnosis of matrix-producing carcinoma (MPC). A breast-conserving mastectomy with sentinel lymph nodes biopsy was performed on the right breast MPC (T1c, N0, M0 Stage I). Histopathologically, the tumor demonstrated overt carcinoma with direct transition to a cartilaginous or osseous matrix and lacked an intervening spindle cell component. Immunohistochemistry showed estrogen receptor (ER) (-), progesterone receptor (PgR) (-), human epidermal growth factor receptor 2 (HER2) (-), and Ki67 index of 50%, so-called triple negative breast cancer. The tumor was also positive for SRY-related HMG box-9 (SOX9), which is a useful marker of chondroid differentiation in normal and neoplastic tissues. The patient lived free from recurrence for 5 years, even though her adjuvant therapy was only radiation therapy without adjuvant chemotherapy. MPC is an uncommon and relatively rare variant of metaplastic carcinoma, and the prognosis for patients with MPC is poorer than that for patients with ordinary breast cancer. Here we report a case of MPC of the breast with characteristic rim enhancement in contrast-enhanced MRI and CT. The intrinsic subtype and prognosis of MPC is controversial, and then we may need more experience with MPC cases.

Download full-text PDF

Source
http://dx.doi.org/10.7888/juoeh.39.167DOI Listing

Publication Analysis

Top Keywords

contrast-enhanced mri
12
rim enhancement
12
matrix-producing carcinoma
8
enhancement peripheral
8
peripheral region
8
breast cancer
8
mpc
7
breast
6
carcinoma
5
tumor
5

Similar Publications

Objectives: To improve preoperative diagnostic accuracy of struma ovarii by retrospectively reviewing magnetic resonance (MR) findings. It is beneficial to choose the most appropriate surgical modality for the patient.

Methods: We retrospectively reviewed the clinical course and MR characteristics of 52 patients who were diagnosed postoperatively with struma ovarii, pathologically, from two institutions.

View Article and Find Full Text PDF

Background: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels to evaluate the efficacy of colorectal cancer liver metastasis (CRCLM) treatment is still rare.

Purpose: To investigate the predictive value of DCE-MRI combined with serum CEA and CA 19-9 concerning the efficacy of comprehensive treatment for CRCLM.

Materials And Methods: A total of 120 patients with CRC were retrospectively recruited using convenience sampling between May 2019 and March 2024.

View Article and Find Full Text PDF

This paper describes the design and initial proof-of-concept of a single pre-clinical transcranial focused ultrasound (FUS) system capable of performing histotripsy (mechanical ablation), hyperthermia, blood-brain barrier opening (BBBO), sonodynamic therapy, or neuromodulation in a murine brain. We have termed it the All-in-One FUS system for murine brain studies, which is the first FUS system of its kind. The 1.

View Article and Find Full Text PDF

Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting.

View Article and Find Full Text PDF

Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma, and many indolent/low-grade NHLs such as follicular lymphoma. Apart from these routinely FDG-avid lymphomas, some indolent NHLs, such as marginal zone lymphoma, are variably FDG-avid; here, [F]FDG PET/CT is an alternative to contrast-enhanced CT at baseline and may be used for treatment response assessment if the lymphoma was FDG-avid at baseline.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!